MERCK TRUSOPT LAUNCH SLATED FOR MID-1995 FOLLOWING FDA APPROVAL
Executive Summary
MERCK TRUSOPT LAUNCH SLATED FOR MID-1995 FOLLOWING FDA APPROVAL of dorzolamide 2% ophthalmic solution for reduction of intraocular pressure in patients with ocular hypertension or open- angle glaucoma on Dec. 9. Trusopt is the first topical carbonic anhydrase inhibitor and received a "1P" priority rating from FDA. The agency completed its review in exactly one year; Merck filed the Trusopt NDA (20-408) on Dec. 10, 1993.